All News
Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides further sustained long-term improvements post 48 weeks in key efficacy outcome measures to 96 weeks of treatment @RheumNow #ACR20 Abstr#1364 https://t.co/972AvDNJDq
Dr. Antoni Chan synovialjoints ( View Tweet)
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
Dr. John Cush RheumNow ( View Tweet)
In the current era, would a positive treat-to-target study in AS change your approach to practice?
(TICOSPA trial ABST1444) #ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Wanna learn about T2T PsA abstracts from #ACR20? Here are my highlights! @RheumNow https://t.co/0X7FF3rwTz
Dr. Rachel Tate uptoTate ( View Tweet)
Check out my video on T2T in SpA abstracts from #ACR20 @RheumNow https://t.co/ZBvmhWyDHU
Dr. Rachel Tate uptoTate ( View Tweet)
We're getting better at treating vasculitis over time.
In-hospital mortality in pts primarily admitted with vasculitis is got much closer to all-comers 1998-2014 (US NIS). Hopefully with more new meds, we've closed the gap even more since!
@UABRheum #ACR20 ABST1423 @RheumNow https://t.co/kNq8HCjqQ0
David Liew drdavidliew ( View Tweet)
Dr. Crow's #StateoftheArt lecture revealed that BEL may be best used in pts with < 2 years and SLEDAI >10 based on the study from Gatto, M et al from 2020. Does this change how you will use BEL in your practice? #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Can hs-troponin and hsCRP predict future major cardiovascular events? Certainly appears so in RA pts (n=636).
To what extent do subclinical dx and inflammation combine to cause future RA CV pain?
PRECISION trial subgroup @ElaineHusniMD @DanielHSolomon #ACR20 ABST1189 @RheumNow https://t.co/ZYTpodatVI
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the annual #ACR2020 meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Robert B Chao, MD doctorRBC ( View Tweet)
The lung-joint axis in RA just keeps on getting stronger
Lung ACPA present in early untreated RA/CSA:
crossreact acetylated/carbamylated antigens
differ in effects on cell types (neut activation, fibroblasts, osteoclasts)
Isn't lung ACPA fascinating?
#ACR20 ABST1445 @RheumNow https://t.co/9VKSRYlndT
David Liew drdavidliew ( View Tweet)
Dr. Jas Singh has shown theres been a decline In-Hospital Mortality in Vasculitis patients over 17 yrs (1998-2014) (using NIS data) #ACR20 Abst#1423 @jasvindermd https://t.co/rMJX5lRrLY https://t.co/aE2rJrMdDh
Dr. John Cush RheumNow ( View Tweet)
National Inpatient Sample claims: ANCA Assoc vasculitis pts hospitalized with acute MI (AMI) had a no increase in mortality rate (5.3% vs. 4.7%) during 2016-2017, suggesting potentially better control w/ new meds (RTX), less steroids #ACR20 Abstr#1424 https://t.co/TYELUAjm9d
Dr. John Cush RheumNow ( View Tweet)
Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient mortality rate (9.17% vs. 4.68%; p=0.001)( (aOR=2.02) #ACR20 Abstr#1390 https://t.co/qWUMkJR40d
Dr. John Cush RheumNow ( View Tweet)
Treat-to-target trials keep getting harder:
- rheum attitudes changed by prev trials so usual care is already v good
- ?less inflamm dx
- more ambitious goals
ASDAS LDA/40/20 and cost-effective not enough?
TICOSPA 'failed' a very high hurdle
@annamolto #ACR20 ABST1444 @RheumNow https://t.co/NWSUvAtouR
David Liew drdavidliew ( View Tweet)
Hispanic/Latino hospitalization rates are overwhelming but not surprising given the huge health care disparities our community faces. #ACR20 #DrFaucisaidso https://t.co/jEVx7cCh7a
Adela Castro AdelaCastro222 ( View Tweet)
Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1
Dr. John Cush RheumNow ( View Tweet)
1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
Dr. John Cush RheumNow ( View Tweet)
Dr. M. “Peggy” Crow’s #StateofArt lecture at #ACR20 reminds us that HCQ is the foundation of tx, to keep prednisone goal < 7.5mg/d, and that BEL works best in early dz (< 2 yrs) Summary slide provided. https://t.co/3LbWqwwOsr
Dr. Rachel Tate uptoTate ( View Tweet)
We were always taught that rheumatic disease ILD is v bad in pregnancy.
Fetal outcomes are def bad in severe ILD, but no maternal deaths/few Cx.
May not need to avoid pregnancy/electively terminate!
Largest-to-date cohort @dukemedicine n=94
@drbags71 #ACR20 ABST1446 @RheumNow https://t.co/E7BDHn8KJb
David Liew drdavidliew ( View Tweet)
